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Heart Transplantation

Impact of New UNOS Allocation Criteria on
Heart Transplant Practices and Outcomes
Jason Liu, MD,1 Bin Q. Yang, MD,1 Akinobu Itoh, MD, PhD,2 Mohammed Faraz Masood, MD,2
Justin C. Hartupee, MD, PhD,1 and Joel D. Schilling, MD, PhD1,3
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Background. In October 2018, a new heart allocation policy was implemented with intent of prioritizing the sickest
patients and decreasing waitlist time. We examined the effects of the new policy on transplant practices and outcomes 1
year before and 1 year after the change. Methods. Transplant recipients from October 2017 to September 2019 at our
institution were identified and divided into 2 cohorts, a preallocation and postallocation criteria change. Patient demographics, clinical data, and bridging strategy were assessed. Early outcomes including ischemic time, severe primary graft dysfunction, need for renal replacement therapy, and duration of hospital stay were investigated. Results. In the 12 months
before the change, 38 patients were transplanted as compared to 33 patients in the 12 months after the change. The average wait-time to transplant decreased after the allocation change (49 versus 313 d, P = 0.02). Patients were more likely to
be bridged with an intra-aortic balloon pump (45% versus 3%) and less likely to be supported with a durable left ventricular
assist device (LVAD) after the change (24% versus 82%). There was an increase in total ischemic time after the change (177
versus 117 min, P ≤ 0.01). There were no significant differences in other early posttransplant outcomes. Conclusions.
Implementation of the new allocation system for heart transplantation resulted in dramatic changes in the bridging strategy
utilized at our institution. Temporary mechanical support usage increased following the change and the number of recipients
supported with durable LVADs decreased. Early posttransplant outcomes appear similar.
(Transplantation Direct 2020;6: e642; doi: 10.1097/TXD.0000000000001088. Published online 15 December, 2020.)

INTRODUCTION
In October 2018, the United Network for Organ Sharing
(UNOS) approved a new heart allocation criteria to prioritize the sickest patients with the goal of reducing waitlist
mortality.1 Changes were made to address the increasing
number of patients on the transplant waiting list, to better
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account for the severity of illness, and to reflect for an
increasing population of patients being supported with a
left ventricular assist device (LVAD).2,3 Notably, the survival rate of patients supported with LVAD without complications have been improving over the past decade,4 and
the established guidelines at the time were not reflective of
these improved outcomes.5
In the new allocation system, the prior 3-tiered system (status 1A, 1B, and 2) was changed to a 6-tiered system (Status
1–6). The current allocation criteria, as outlined in the Organ
Procurement and Transplantation Network (OPTN) policy,
are described in Table 1. Status 1A was divided into 3 separate categories (status 1, 2, and 3), while status 4 was created
to correspond to the previous status 1B. As an example, under
the previous criteria, a patient on venoarterial extracorporeal
membrane oxygenation (VA-ECMO) and a stable patient on
LVAD support who is using his or her discretional 30 days of
Elective 1A time would have the same listing status. However,
under the new criteria, those patients would instead be listed
as status 1 and status 3, respectively. This stratification better
reflects the severity of their illness and prioritizes the patient
with the greatest chance of death while awaiting transplant.
Stable patients with durable LVAD support are now listed as
status 4 under the new allocation criteria instead of status
1B.6,7 In addition to changes in listing status, a geographical
range of 500 nautical miles was instituted from the site of the
donor hospital in an effort to prioritize available organs based
on illness severity rather than geography.6
www.transplantationdirect.com
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MATERIALS AND METHODS

TABLE 1.

Change in heart allocation criteria resulting in a new
6-tiered system
Old
New
allocation allocation
system
system
Status 1

Status 1A Status 2

Status 3

Status 1B Status 4

Status 2

Status 5
Status 6
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Listing criteria
• VA-ECMO
• Nondischargeable, surgically implanted, nonendovascular
biventricular support device
• MCSD with life-treatening ventricular arrhythmia
• IABP
• Nondischargeable, surgically implanted, nonendovascular
LVAD
• VT or VF without mechanical support
• MCSD with device malfunction or failure
• TAH, BiVAD, RVAD, or VAD for single ventricle patients
• Percutaneous endovascular MCSD
• Dischargeable LVAD for discretionary 30 d
• Multiple inotropes or single high-dose inotrope with
continuous hemodynamic monitoring
• Single inotrope with continuous monitoring
• VA-ECMO after 7 d; IABP or percutaneous endovascular
circulatory support device after 14 d
• Nondischargeable, surgically implanted, nonendovascular
LVAD after 14 d
• Mechanical support device with complication
• Dischargeable LVAD without discretionary 30 d
• Inotropes without hemodynamic monitoring
• Retransplant
• Diagnosis of CHD, ischemic heart disease with intractable
angina, hypertrophic CM, restrictive CM, amyloidosis
• On waitlist for at least one other organ at the same hospital
• All other active candidates

The new adult heart allocation criteria and its corresponding status from the previous criteria for
medical urgency status is adopted from the OPTN website and policies, of which full details can
be found at https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.
CHD, congenital heart disease; CM, cardiomyopathy; ECMO, venoarterial extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; (R/L) VAD, (right/left) ventricular assist device;
TAH, total artificial heart; VA-MCSD, mechanical circulatory support device; VF, ventricular fibrillation; VT, ventricular tachycardia.

Preliminary data presented in a 4-month report in April
2019 published by the OPTN Thoracic Committee demonstrated no major impact on the number of registrations made
to the waiting list or the number of transplants performed,
although it did report a significant increase in ischemic time.8
Newer data from the UNOS and OPTN registries have
emerged regarding the effects of the new allocation criteria,
revealing a shift in bridging strategies and a focus on temporary mechanical support. The percentage of patients supported
by LVAD at the time of transplant has decreased significantly,
whereas those supported by VA-ECMO and intra-aortic balloon pump (IABP) have increased.9-11 While an early analysis
of the UNOS registry suggested worsening posttransplantation
outcomes,9 a study of the OPTN registry at the 1-year mark
did not show significant change observed in either waiting list
mortality nor posttransplant survival after the policy change
was instituted.11 However, the effect of the new allocation
system on the types of temporary mechanical support being
utilized, trends in clinical care at the institutional level, and
early outcomes other than mortality is less well understood.
Therefore, we sought to investigate how the new allocation
criteria impacted patients transplanted at a single institution 1
year before and 1 year after the allocation change.

Study Population
This was a retrospective cohort study that examined
all adult patients who underwent heart transplantation at
Barnes-Jewish Hospital/Washington University in St. Louis
from October 2017 to September 2019. Patients were divided
into two groups based on if they were transplanted before or
after October 18, 2018, the date of the allocation change.
Data were gathered through review of electronic medical
record, including baseline demographics, laboratory values,
bridging strategy (none, IV inotropes, temporary mechanical
devices such as IABP or LVAD), patient- and donor-specific
factors, and early outcomes including the presence of severe
primary graft dysfunction (PGD), need for renal replacement therapy (RRT) or tracheostomy after transplantation,
duration of intensive care unit (ICU) stay, and total length of
hospital stay. Study data were collected and managed using
REDCap (Research Electronic Data Capture) tools hosted at
Washington University in St. Louis. REDCap is a secure, webbased software platform designed to support data capture for
research studies.12,13
Statistical Analysis
Continuous variables were analyzed using a 2-tailed t-test,
while categorical variables were analyzed using Chi-square or
Fisher exact test. A P value <0.05 was considered statistically
significant. Data analysis was performed using Stata Statistical
Software (Release 16, College Station, TX). This study was
reviewed and approved by the Washington University in St.
Louis Institutional Review Board.

RESULTS
Demographics and Baseline Clinical Data
In total, 71 patients were identified, with 38 patients transplanted the year before the change compared to 33 patients
the year after the change. Baseline characteristics for each
group are listed in Table 2. Compared with the year prior,
patients that were transplanted after the allocation change
had lower serum sodium and hemoglobin and higher total
bilirubin and hemoglobin A1c. The most common reported
etiology of heart failure was nonischemic cardiomyopathy
in both cohorts, 68% (26/38) the year before versus 73%
(24/33) the year after (P = 0.69). Single organ transplantation was performed most often, with 95% (36/38) the year
before versus 97% (32/33) the year after (P = 0.64). While the
average donor age did not change significantly, the amount
of organ donations accepted from local organ procurement
organizations decreased significantly from 97% (37/38) the
year before to 33% (11/33) the year after (P < 0.01).
Listing Information
The most common listing status before the allocation
change was status 1B [28/38 (74%)]. Of the 10 patients listed
as status 1A, 3 were inpatient before the change. One required
inotropic support, one required IABP support, and the third
was listed as a 1A exception for ventricular tachycardia. The
other 7 patients were called in as an outpatient and were
listed as status 1A exception due to pump malfunction, hemorrhagic stroke, hemolysis, aortic insufficiency, or refractory
GI bleeding. The most common listing status after the allocation change was status 2 [19/33 (60%); Figure 1]. Of the

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 2.

Baseline characteristics and clinical data

Age (y)
Male sex
Caucasian race
Body mass index (kg/m2)
Sodium (mEq/L)
Creatinine (mg/dL)
Total bilirubin (mg/dL)
AST (units/L)
ALT (units/L)
Albumin (g/dL)
Hemoglobin (g/dL)
NT-proBNP (pg/mL)
Hemoglobin A1c
Blood type
A
B
O
AB
HF etiology
Ischemic
NICM
CAVa
Organ transplanted
Heart
Heart/kidney
Heart/liver
Donor age (y)
Local donor

Before allocation
change (N = 38)

After allocation
change (N = 33)

P

53
71%
76%
29.3
139
1.4
0.7
37
28
4.1
12.0
5734
5.8%

54
70%
67%
27.5
135
1.4
1.0
39
40
4.0
11.0
5645
6.4%

0.75
0.90
0.37
0.12
<0.01
0.99
0.05
0.72
0.16
0.26
0.02
0.98
<0.01

19
2
16
1

13
4
12
4

0.37
0.41
0.62
0.17

10
26
2

7
24
2

0.62
0.69
1

36
1
1
27
97%

32
1
0
27
33%

0.64

0.80
<0.01

Two patients each in the year before the change as well as the year after had coronary allograft
vasculopathy, requiring redo orthotopic heart transplantation.
CAV, coronary allograft vasculopathy; NICM, nonischemic cardiomyopathy.

a

19 patients listed as status 2, 15 were supported with IABP,
while the remaining four patients were listed as status 2 due to
LVAD malfunction. All status 1 patients were supported with
ECMO. After the change, there was a statistically significant
decrease in days spent on the transplant waitlist from 314 to
49 days (P = 0.02; Table 3).
Shift in Bridging Strategy Utilized
There was a dramatic decrease in patients supported with
LVAD at the time of transplant, from 82% (31/38) the year
before the allocation change to 24% (8/33) the year after

3

(P < 0.01; Table 3). In contrast, under the new allocation system, use of IABP increased from 3% (1/38) to 45% (15/33;
P < 0.01). There was a suggestion of increased use of
VA-ECMO (0% versus 9%, P = 0.1); however, other bridging
strategies such as inotropic support and redo transplantation
were not statistically different before and after the allocation
change (Figure 2).
Increasing Use of IABP
The increased use of IABP as a bridging strategy corresponded with increased insertion of IABP via the axillary approach after the allocation change (0% versus 68%;
Table 4). Under the new allocation system, 19 patients in total
had the use of either femoral or axillary IABP as a bridging
strategy, with 15 of those able to be transplanted as status 2.
Of the 4 other patients, 2 received heart transplants after utilization of a different bridging strategy. One required escalation to VA-ECMO and was eventually transplanted as status
1, and the other experienced bleeding complications necessitating IABP removal and was bridged to transplant on inotropes as a status 3. Further complications necessitating IABP
exchange or removal are listed in Table 4. During the study
period under the new allocation criteria, 2 other patients who
were supported with IABP passed away before transplant due
to refractory shock. In both cases, LVAD implantation was
not an option due to severe biventricular dysfunction.
Trends in Clinical Care
After the allocation change, patients were less likely to be
outpatient at the time of heart transplant. The year before the
change, 92% (35/38) of patients were called in from home to
be admitted to the hospital to receive their heart transplant,
compared with 30% (10/33) the year after. This coincides with
increased length of stay in the hospital before heart transplant
after the system change (5 versus 14 d, P = 0.01; Table 5).
To evaluate how our center adjusted to the new allocation
system, we assessed transplant volume by quarter over this
2-years window. As seen in Figure 3, transplant volumes per
quarter remained consistent until the allocation change, after
which there was a considerable decrease in the first 2 calendar quarters. Over time, clinical practice was adjusted to align
with the prioritization scheme of the new system, resulting in
an increase in transplant volume over the final two quarters
of the year.
Early Outcomes
A statistically significant increase in cold ischemic time was
seen under the new system with an average of 177 minutes

FIGURE 1. Listing status of heart transplants preallocation and postallocation criteria change.
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TABLE 4.

TABLE 3.

Transplant listing data, including bridging strategy utilized
before and after heart allocation change
Before allocation After allocation
change (N = 38) change (N = 33)
Days on transplant list
Called in as outpatienta (n, %)
Bridging strategy (n, %)
VAD
  HM2
  HM3
  HVAD
IABP
Inotropic support
VA-ECMO
Redo OHT
Noneb

Patients bridged with IABP before and after heart allocation change

P

314
35 (92)

49
10 (30)

0.02
<0.01

31 (82)
15
8
8
1 (3)
3 (8)
0 (0)
2 (5)
1 (3)

8 (24)
2
1
5
15 (45)
5 (15)
3 (9)
2 (6)
0 (0)

<0.01

<0.01
0.46
0.10
1
1

Patients who were called in to the hospital while outpatient for admission to receive their heart
transplant were listed as such, compared to patients that were already hospitalized for decompensated heart failure when they received their transplant.
b
One patient was admitted with multiple shocks from an implanted cardiac defibrillator and was
listed as a status 1A exception for ventricular tachycardia. This patient went into PEA arrest after
attempted defibrillation threshold testing and stayed in the hospital over 3 mo before transplant.
The patient did not receive inotropic support or mechanical device support at any time during
the hospitalization.
HM2, HeartMate 2; HM3, HeartMate 3; HVAD, HeartWare VAD; IABP, intra-aortic balloon pump;
OHT, orthotopic heart transplant; VA-ECMO, venoarterial extracorporeal membrane oxygenation;
VAD, ventricular assist device.
a

compared with 117 minutes before the change (P < 0.01;
Table 5). Otherwise, there were no statistically significant differences in any other measured outcomes, including the overall number of days intubated, presence of severe PGD, days
on vasopressor and inotropic support after transplant, use of
RRT, need for tracheostomy, postoperative infection, treated
rejection at 6 months, overall ICU length of stay, or length of
stay in the hospital after heart transplantation. Of note, nearly
all cases of PGD occurred in patients who went into transplant on LVAD support (Table 5). There was a nonstatistically
significant increase in posttransplant mortality after the allocation change with 3 patients occurring the year after compared with zero patients the year prior. All 3 deaths occurred
in patients supported with a durable LVAD.

Patients bridged with IABP
Transplanted as status 2 (n, %)
Transplanted as different statusa
Passed away before transplant
Mean days with IABP
Axillary IABP placement (n, %)
Complicationsb (n, %)
Balloon rupture
Bacteremia
Kinking of catheter shaft
Bleeding
Limb ischemia

Before
allocation change

After
allocation change

1
1 (100)
0
0
6
0
0
0
0
0
0
0

19
15 (79)
2 (11)
2 (11)
13
13 (68)
5 (26)
1
1
1
1
1

Two patients initially started out with IABP bridging. One required escalation with VA-ECMO and
was up-listed and eventually transplanted as status 1. The other had IABP removal due to bleeding complication and was transplanted as status 3.
b
Balloon rupture and bacteremia required axillary IABP exchange, kinking of the catheter shaft
required replacement from axillary to femoral positioning, bleeding resulted in IABP removal, limb
ischemia necessitated thrombectomy and IABP removal.
IABP, intra-aortic balloon pump; VA-ECMO, venoarterial extracorporeal membrane oxygenation.
a

DISCUSSION
Our study illustrates the profound impact of the new UNOS
allocation system on transplant practices at a large tertiary
academic center. Using the 12 months before the implementation of the system as a control, our data revealed a significant
decrease in the number of patients transplanted who were
bridged with a durable LVAD and a simultaneous increase in
patients who were supported with an IABP. This was associated with a significant reduction in time on the waitlist before
transplant. After the change, patients were more likely to be
hospitalized for several weeks before transplant, and ischemic
time was increased. However, posttransplant outcomes were
similar between the cohorts.
Our experience has been compatible with other recent
analyses demonstrating the shift in bridging strategy following the allocation change. An early investigation of the
UNOS registry reported that among patients receiving a heart

FIGURE 2. Bridging strategy before and after the allocation change. Patients transplanted after the heart allocation change were significantly
more likely to be bridged with an IABP and less likely to be bridged with durable LVAD. IABP, intra-aortic balloon pump; LVAD, left ventricular
assist device; OHT, orthotopic heart transplant.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 5.

Early outcomes after heart transplantation

Ischemic time (min)
Days intubated
Days in ICU
Days in hospital before OHT
Days in hospital after OHT
Severe PGD (n, %)
PGD patients with LVAD
% LVAD patients with PGD
Days on vasopressors/inotropes
vasopressors >7 d (n, %)
Usage of RRT (n, %)
Tracheostomy (n, %)
Infection (n, %)
Treated rejection (n,%)
Expired (n, %)

Before allocation
change (N = 38)

After allocation
change (N = 33)

117
3
7
5
7
6 (16)
6 (100)
19%
8
16 (42)
12 (32)
4 (11)
8 (21)
8 (21)
0 (0)

177
3
9
14
9
5 (15)
4 (80)
50%
7
9 (27)
14 (42)
6 (18)
9 (27)
3 (9)
3 (9)

P
<0.01
0.82
0.33
0.01
0.33
1
0.12
0.19

0.34
0.50
0.54
0.16
0.10

ICU, intensive care unit; OHT, orthotopic heart transplant; PGD, primary graft dysfunction; RRT,
renal replacement therapy.

transplant those bridged with LVADs decreased from 42% to
23%, while those bridged with temporary mechanical support increased from 10% to 41% after the allocation change.9
Another recent study by Varshney et al14 demonstrated a
significant increase in temporary mechanical circulatory
support (MCS) among patients with acute decompensated
heart failure in the US transplant centers. At our institution,

5

the use of IABP as a bridging strategy increased significantly
from 3% to 45% after the allocation change. Furthermore,
68% of patients who received IABP had the device placed in
the axillary position, which has been shown to represent a
well-tolerated bridging strategy.15 IABP complications necessitating removal or exchange occurred in 26% of cases at
our center. These results are comparable to recent study by
Bhimaraj et al,16 who reported that in a large series of patients
with axillary IABP insertion that 15.8% required at least one
IABP replacement. Two other reviews have suggested vascular complication rates of 8%–18%17 and 0.94%–31.1%.18 In
our series, 79% of IABP bridged patients successfully made
it to transplant, further supporting the concept that this is an
acceptable strategy to bridge patients to transplant. In comparison, other studies have shown rates of ~70% success in
bridging patients with axillary IABP support to transplant or
LVAD.16 Similar findings have also been reported using the
Impella 5.0 as a bridge to durable MCS or heart transplant.19
Another striking observation was that the lower priority
assigned to those on LVAD support (status 4) has resulted in
fewer of these patients receiving a heart transplant, a finding echoed in recent analyses of the UNOS9 and OPTN10,11
registries. At our institution, only 3 patients (9%) were transplanted from a status 4 listing under the new allocation criteria. The other 5 patients on durable LVAD support were
up-listed due to complications related to their LVAD. The
combination of a lower listing status along with an increase
in geographic range for available donors has led to decreased
offers for status 4 patients when compared with status 1B
patients the year prior. Thus, the new system has increased

FIGURE 3. Transplant volume by calendar quarter. Transplant volume was lowest in the two quarters immediately following the allocation
change on October 18, 2018. ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; OHT, orthotopic heart transplant;
VAD, ventricular assist device.
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wait times for those who are doing well on LVAD support.
This has created a system of practice where durable MCS
and transplant are effectively parallel pathways rather than
events in series. Although there may be some advantages to
this approach moving forward, it has disadvantaged many
LVAD patients who were implanted as a bridge to transplant before the allocation change. In addition, the practice
of only transplanting LVAD patients with complications has
the potential to worsen both short-term and long-term transplant outcomes.
There have been concerns in the transplant community that
the changes in the new allocation policy designed to reduce
death on the waitlist could worsen posttransplant outcomes.
In particular, the combination of increased allograft ischemic
time and more severe illness in recipients has been considered a
recipe for early complications such as PGD. Although an early
analysis of the UNOS registry reported by Cogswell et al9 found
a significant increase in post-heart transplant death in the new
system, analysis of the OPTN data by Goff et al11 did not show
significant change in posttransplant survival at the 1-year mark.
Similar to other studies,8,9,11 we observed a significant increase
in ischemic time under the new allocation system. This was
likely a result of a significant increase in accepted organs from
outside our local organ procurement organization. However,
despite the longer ischemic time and increased use of temporary
support, we did not observe significant differences in the use of
RRT, tracheostomy, length of stay in the ICU, length of stay in
the hospital, or severe PGD after transplant. In fact, 91% of the
severe PGD occurred in those with LVADs in both years of this
study. This observation is in line with prior data that LVADs
are a major risk factor for PGD.20 A concerning finding is that
under the new system severe PGD occurred in 50% of patients
who had an LVAD going into transplant. This may be a consequence of the new system favoring organ allocation to LVAD
patients with complications. To this point, we recently demonstrated that patients with the right heart failure on LVAD support are at higher risk of PGD posttransplant compared with
stable patients on LVAD support.21
Although our study was too small to address mortality concerns, there were 3 patients who expired the year
after the change. All of these patients were supported with
LVADs and the cause of death was attributable to complications of severe PGD. At the time of this reporting, there
were no further deaths among patients transplanted in the
year after the allocation change. Thus, we conclude that
increased use of temporary support devices and longer
ischemic times did not worsen early posttransplant outcomes at our institution. Rather, the mortality observed in
our study was seen only in patients supported with LVADs.
Further investigation of these relationships in larger patient
series’ with longer follow-up will be necessary to delineate
the implications of the allocation change on early and late
posttransplant outcomes.

LIMITATIONS
First, this a single-center study with a limited sample size,
and the results cannot necessarily be generalized to clinical
practice at other institutions. However, over the study period,
all heart transplants were evaluated by the same groups of
advanced heart failure physicians and cardiac surgeons at our
institution. Next, this study was performed at the 1-year mark
of allocation change, and only short-term outcomes were

available. Finally, this study was not large enough to address
the increasing use of VA-ECMO. At our institution, 9% of
patients were bridged with VA-ECMO successfully; however,
this approach must be used carefully.22

CONCLUSION
Implementation of the new heart allocation system at our
institution resulted in dramatic changes in utilization of the
bridging strategy for transplantation. Patients were less likely
to be supported with durable LVADs and were more likely to
be supported by IABP after the allocation change, resulting in
decreased days on the waitlist and increased inpatient hospital
length of stay before the transplant. Early posttransplant outcomes appear similar. Further monitoring of posttransplant
outcomes will be needed to evaluate the longer-term effects of
the allocation criteria changes.
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